The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab deruxtecan) makes it to market and meets sales targets. If that does happen, HER2 inhibitor ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

Daiichi Sankyo US continues to redefine the classification and treatment of metastatic breast cancer, and our passion for innovation and compassion for patients brings hope for patients seeking ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

To recap, NTK in October 2023 filed a lawsuit in the Tokyo District Court alleging that Daiichi Sankyo caused losses by preventing NTK from proceeding with open offers to buy a stake in Indian ...